Nightstar (NITE) Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Nightstar Therapeutics Plc is Fair to Nightstar Shareholders – NITE
NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the sale of Nightstar Therapeutics plc (“Nightstar” or the “Company”) (NASDAQ: NITE) to Biogen Inc. (“Biogen”) is fair to Nightstar shareholders.
If you are a Nightstar shareholder and would like to discuss your legal rights and options, please visit Nightstar (NITE) Merger Investigation or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or firstname.lastname@example.org or email@example.com.
The investigation concerns whether Nightstar and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Nightstar shareholders; (2) determine whether Biogen is underpaying for Nightstar; and (3) disclose all material information necessary for Nightstar shareholders to adequately assess and value the merger consideration.
On behalf of Nightstar shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
If you are a Nightstar shareholder and would like to discuss your legal rights and options, please visit https://halpersadeh.com/actions/nightstar-therapeutics-plc-nite-merger-biogen-stock/ or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or firstname.lastname@example.org or email@example.com.
Our attorneys represent investors all over the world who have fallen victim to securities fraud and corporate misconduct. They have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.